Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 19/20 | 0.76 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.54 |
| ▸ | HTR2A | P28223 | 4/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.51 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7741453 | 0.88 | SLC6A4 (0.59) | SLC6A4SLC6A3HRH3SLC6A2HTR2A | |
| SCHEMBL7946261 | 0.87 | SLC6A4 (0.70) | SLC6A4SLC6A3HRH3SLC6A2HTR2A | |
| SCHEMBL7735932 | 0.87 | SLC6A4 (0.63) | SLC6A4SLC6A3SLC6A2HTR2AKCNH2 | |
| SCHEMBL6152231 | 0.87 | SLC6A4 (0.57) | SLC6A4SLC6A3HRH3HTR2AKCNH2 | |
| SCHEMBL3361717 | 0.86 | SLC6A4 (0.69) | SLC6A4SLC6A3HRH3SLC6A2SOS1 | |
| SCHEMBL3362794 | 0.86 | SLC6A4 (0.79) | SLC6A4SLC6A3HRH3SLC6A2SOS1 | |
| SCHEMBL930692 | 0.86 | SLC6A4 (1.00) | SLC6A4SLC6A3SLC6A2SOS1 | |
| SCHEMBL30682154 | 0.86 | SLC6A4 (1.00) | SLC6A4SLC6A3SLC6A2SOS1 | |
| SCHEMBL3360984 | 0.86 | SLC6A4 (0.68) | SLC6A4SLC6A3HRH3SLC6A2HTR2A | |
| SCHEMBL7737285 | 0.86 | SLC6A4 (0.68) | SLC6A4SLC6A3HRH3SLC6A2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8475804-B2 | Compositions and methods for treatment of filovirus-mediated diseases | U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND (US) | 2013-07-02 | — | — | US | disclosed |
| WO-2010021681-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-02-25 | — | — | WO | disclosed |
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | HTR1A, HTR3B, HTR3A | SLC6A4 34/4885SLC6A3 226/4885HRH3 495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.